论文部分内容阅读
[目的]探讨可溶性B7-H4在乳腺癌血清中表达情况及其与临床病理因素相关性。[方法]建立检测可溶性B7-H4的间接ELISA法,对37例术后乳腺癌患者血清样本进行检测,分析其与绝经与否、肿瘤大小、淋巴结转移、肿瘤分期、ER和PR表达、Her-2/neu状态的相关性。[结果]建立的夹心ELISA法检测B7-H4的线性范围为3.13～200μg/L,37例术后乳腺癌患者血清B7-H4的含量为42.52±16.63μg/L,含量的高低与肿瘤中Her-2/neu状态、绝经与否相关,Her-2/neu阳性患者血清中表达显著高于阴性患者(P<0.05),绝经后患者B7-H4表达明显高于绝经前患者(P<0.05)。[结论]乳腺癌血清可溶性B7-H4的含量可能与其预后及进展相关。
[Objective] To investigate the expression of soluble B7-H4 in breast cancer serum and its correlation with clinicopathological factors. [Methods] Serum samples of 37 postoperative patients with breast cancer were detected by indirect ELISA to detect soluble B7-H4. The correlations were analyzed with those of menopause or not, tumor size, lymph node metastasis, tumor stage, ER and PR expression, Her- 2 / neu status of the relevance. [Results] The linear range of sandwich ELISA was 3.13 ~ 200μg / L. The serum level of B7-H4 was 42.52 ± 16.63μg / L in 37 cases of postoperative breast cancer. The level of B7- (P <0.05). The expression of B7-H4 in postmenopausal patients was significantly higher than that in premenopausal patients (P <0.05) . [Conclusion] The content of serum soluble B7-H4 in breast cancer may be related to its prognosis and progress.